Literature DB >> 31814602

Inflammatory and nutritional status is a predictor of long-term outcome in patients undergoing surgery for gastric cancer. Validation of the Naples prognostic score.

Gennaro Galizia, Annamaria Auricchio, Ferdinando de Vita, Francesca Cardella, Andrea Mabilia, Nicoletta Basile, Michele Orditura, Eva Lieto.   

Abstract

PURPOSE: Oncological outcome depends not only on tumor behaviour but also on nutritional and immune-inflammatory host status. Data in gastric cancer are limited. The main aim of this study was to prospectively assess Naples prognostic score (NPS) in gastric cancer patients. NPS was also compared with prognostic nutritional index (PNI), controlling nutritional status (CONUT) score and systemic inflammation score (SIS).
METHODS: Overall survival (OS) and complication rates of 415 patients undergoing gastric cancer surgery from January 2000 to December 2015 were calculated. Disease-free survival (DFS) rates were assessed in 307 radically resected patients. MaxStat analysis was used to identify the best cut-off values. NPS scores were divided into 3 groups (NPS 0-3). The receiver-operating-characteristic (ROC) curve for censored survival data was used to compare the prognostic performance of scoring systems.
RESULTS: NPS positively correlated with current scoring systems (p<0.001) and advanced tumor stages (p<0.001). Patients with elevated NPS scores experienced more postoperative complications (all patients: p=0.003; radically resected patients: p=0.010). NPS1 and NPS2 patients had a higher hazard ratio (HR) than NPS0 patients for OS (NPS1 HR 2.04, NPS2 HR 4.27; p<0.001) and DFS (NPS1 HR 1.70, NPS2 HR 4.98; p<0.001). Among the different scoring systems, only NPS was selected as an independent significant predictor for OS (p=0.024) and DFS (p=0.009). NPS was assigned the best prognostic performance by ROC analysis, equalling TNM staging system, and correctly identified highrisk patients.
CONCLUSIONS: NPS is an easy to calculate prognostic score strongly associated with outcome in patients undergoing gastric cancer surgery. KEY WORDS: Gastric cancers, Immune-nutritional and inflammatory host status, Naples prognostic score.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31814602

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  6 in total

1.  Survival Prediction Capabilities of Preoperative Inflammatory and Nutritional Status in Esophageal Squamous Cell Carcinoma Patients.

Authors:  Kotaro Sugawara; Koichi Yagi; Yasuhiro Okumura; Susumu Aikou; Hiroharu Yamashita; Yasuyuki Seto
Journal:  World J Surg       Date:  2022-01-09       Impact factor: 3.352

2.  Value of Preoperative Hematological Parameters in the Prognosis of Gastric Cancer Patients Undergoing a Total Gastrectomy.

Authors:  Xi-Shan Zhu; Ye Zhao; Fei-Yan Ma; Shi-Kai Wu
Journal:  Curr Med Sci       Date:  2022-04-13

3.  CONUT Score or/and Peripheral Blood CD4+/CD8+ Ratio-Based Web Dynamic Nomograms to Predict the Individualized Survival of Patients with Advanced Osteosarcoma.

Authors:  Qian-Kun Yang; Yan-Na Su; Wei Wang; Zhong-Xiang Yao; Nan Wang; Xiao-Jing Zhang
Journal:  Cancer Manag Res       Date:  2020-06-03       Impact factor: 3.989

4.  The role of prognostic nutritional index for clinical outcomes of gastric cancer after total gastrectomy.

Authors:  Zhu Xishan; Zhao Ye; Ma Feiyan; Xuan Liang; Wu Shikai
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

5.  Prognostic Importance of the Preoperative Naples Prognostic Score for Patients With Adenocarcinoma of the Esophagogastric Junction.

Authors:  Jianping Xiong; Yaqin Wang; Wenzhe Kang; Fuhai Ma; Hao Liu; Shuai Ma; Yang Li; Peng Jin; Haitao Hu; Yantao Tian
Journal:  Front Oncol       Date:  2020-12-16       Impact factor: 6.244

6.  Naples Prognostic Score: A Novel Prognostic Score in Predicting Cancer-Specific Survival in Patients With Resected Esophageal Squamous Cell Carcinoma.

Authors:  Ji-Feng Feng; Jian-Ming Zhao; Sheng Chen; Qi-Xun Chen
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.